Sugi Predict

Sugi Predict / Compounds / Cilexetil

Cilexetil

Cilexetil

SCHEMBL3483374

CC(C)OC(=O)OC1CCCCC1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 3/20 0.44
▸ CYP19A1 P11511 3/20 0.42
▸ NAAA Q02083 2/20 0.41
▸ HTT P42858 1/20 0.40
▸ CYP2C19 P33261 2/20 0.38
▸ CA12 O43570 4/20 0.38
▸ CA1 P00915 4/20 0.38
▸ CA2 P00918 4/20 0.38
▸ CA9 Q16790 4/20 0.38
▸ TSHR P16473 2/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MMP2 P08253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16731836 1.00 EPHX1 (0.44) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL3483069 0.98 EPHX1 (0.41) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL1078204 0.96 EPHX1 (0.46) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL1080567 0.91 EPHX1 (0.42) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL2422669 0.91 EPHX1 (0.42) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL22367794 0.90 EPHX1 (0.41) EPHX1CYP19A1NAAAHTTCYP2C19
SCHEMBL3483142 0.89 TSHR (0.40) EPHX1CYP19A1TSHR
SCHEMBL1083473 0.89 TSHR (0.40) EPHX1CYP19A1TSHR
SCHEMBL1081363 0.86 SERPINE1 (0.39) EPHX1CYP19A1NAAATSHR
SCHEMBL1240113 0.86 EPHX1 (0.43) EPHX1CYP19A1NAAAHTTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228525-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects ARBOR PHARMACEUTICALS, LLC 2021-07-29 — — US claimed
US-20140350018-A9 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-11-27 — — US claimed
US-20140057917-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-02-27 — — US claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 — — EP disclosed
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors CARDURION PHARMACEUTICALS, INC. (US) 2026-01-20 — — US disclosed
EP-4604721-A2 PORPHYRIA DISEASE MODELS Agios Pharmaceuticals, Inc. (US) 2025-08-27 — — EP disclosed
CN-120152617-A Porphyrin disease model 安吉奥斯医药品有限公司 2025-06-13 — — CN disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
CN-119384294-A Anticholinergic agents and muscarinic agonists for the treatment of Demodex related conditions 阿提莱普斯控股有限公司 2025-01-28 — — CN disclosed
US-20240276957-A1 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. 2024-08-22 — — US disclosed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 — — US disclosed
EP-0972776-B1 A phosphine sulfide, a manufacturing process therefor and a use thereof MITSUI CHEMICALS INC (JP) 2003-04-23 — — EP disclosed
US-6153794-A Phosphine sulfide, a manufacturing process therefor and use thereof MITSUI CHEMICALS, INC. (JP) 2000-11-28 — — US disclosed
CN-1262276-A Phosphine sulfide preparing process and use thereof MITSUI CHEMICALS INC (JP) 2000-08-09 — — CN disclosed
EP-0972776-A1 A phosphine sulfide, a manufacturing process therefor and a use thereof Mitsui Chemicals, Inc. (JP) 2000-01-19 — — EP disclosed
EP-0748364-A4 UNLEADED MMT FUEL COMPOSITIONS ORR WILLIAM C (US) 1997-07-23 — — EP disclosed
EP-0748364-A1 UNLEADED MMT FUEL COMPOSITIONS ORR, William C. (US) 1996-12-18 — — EP disclosed
WO-1995023836-A1 UNLEADED MMT FUEL COMPOSITIONS ORR WILLIAM C (US) 1995-09-08 — — WO disclosed
EP-0474342-A1 Unsymmetrical dialkyl carbonate fuel additives ARCO Chemical Technology, L.P. (US) 1992-03-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors RYR2, CACNA1C, CAMK4 EPHX1 3730/4885CYP19A1 4182/4885NAAA 3300/4885
US-20140057917-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA EPHX1 1551/4885CYP19A1 438/4885NAAA 580/4885
US-20140350018-A9 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA EPHX1 1551/4885CYP19A1 438/4885NAAA 580/4885
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 EPHX1 929/4885CYP19A1 1254/4885NAAA 731/4885
US-20210228525-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects FH, FAH, ALDOA EPHX1 1551/4885CYP19A1 438/4885NAAA 580/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE EPHX1 927/4885CYP19A1 3157/4885NAAA 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.